Mergers & acquisitions
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics.
A look at why a potential buyout of Acadia might not be as likely as some have suggested.
Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative.
Both Amazon and Rite Aid offered no comment for this story.
There were five fatalities out of seven patients with sepsis, all in the tozadenant group.
Bloomberg noted that Takeda’s CEO is looking at making Takeda a nimble company, but one with a deeply entrenched R&D focus.
Shares of Merit Medical Systems have jumped more than 9 percent this morning after the company announced it plunked down $100M for two product lines belonging to Becton, Dickinson and Company.
The company sold the stake to Sapphire I Holdings at an undisclosed price.
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS.
PRESS RELEASES